|
|
||
|
|
United States Patent: 6,019,968 Inventors: Platz; Robert M. (Half Moon Bay, CA); Patton; John S. (San Carlos, CA); Foster; Linda C. (Mountain View, CA); Eljamal; Mohammed (Tripoli, LB)Assignee: Inhale Therapeutic Systems, Inc. (San Carlos, CA) Appl. No.: 951312Filed: October 16, 1997 This invention relates to dispersible antibody compositions and methods for preparing and using these compositions. In particular, the present invention relates to dry powder dispersible antibody compositions wherein antibody conformation is preserved. The compositions have good powder dispersibility and other desirable characteristics for pulmonary delivery of therapeutic antibodies. SUMMARY OF THE INVENTION The present invention provides dispersible dry powder
antibody compositions and methods for their preparation and use. These
dispersible dry powder antibody compositions have a moisture content of
less than about 10% by weight (% w) water, usually about 1-5% by weight,
and preferably less that about 3% by weight of water. They have a particle
size of about 0.1 to 7 .mu.m mass median diameter (MMD), usually about 0.4
to 5 .mu.m MMD, preferably about 1 to 4 .mu.m and most preferably about
1-3 .mu.m MMD. The dispersible dry powder antibody compositions of the
present invention result in a delivered dose of greater than about 30%,
usually greater than about 40%, preferably greater than about 50% and most
preferably greater than about 60%. They have an aerosol particle size
distribution of about 1-5 .mu.m mass median aerodynamic diameter (MMAD),
usually about 1.5-4.5 .mu.m MMAD and preferably about 1.5-4.0 .mu.m MMAD,
or with at least about 40% (preferably at least about 50%) of the
particles less than about 3.3 .mu.m in diameter. The compositions contain
at least about 40% by weight antibody. Further, the antibodies in these
compositions are not aggregated and are present in their native
conformation so as to retain their biological activity. Claim 1 of 13 Claims 1. An IgG antibody-based dry powder composition for
pulmonary delivery comprising a predetermined amount of IgG antibody which
is non-aggregated and is in its native conformation in respirable dry
powder particles having a particle size less than 10 micrometers wherein
said composition has a delivered dose efficiency of at least about 30%.
____________________________________________
|
|
|